The legal protection that let a pharmaceutical company recoup the billions it spent developing a life-saving cancer drug is the same legal protection that priced a dying woman out of the one treatment that could have saved her.

Every Patent Upheld Funds Tomorrow's Cure. Every Patent Enforced Prices Someone Out Of Today's. In 2022, a

retired bank employee with HER2-negative metastatic breast cancer went to the Kerala High Court asking it to compulsorily license Ribociclib - a patented drug she could not afford, under Sections 92 and 100 of the Patents Act, 1970.

The court agreed the Centre should consider it. The case was then listed for hearing 57 more times. She died before any of those hearings produced a decision. The easy answer would be: obviously, revoke the patent, save the patient.

But that answer skips the other half of the same system. Ribociclib exists because a pharmaceutical company spent years and enormous capital developing it, recovered largely through the very patent protection this patient needed lifted.

Every drug currently saving lives was developed under the expectation that its patent would hold long enough to be profitable. Weaken that expectation broadly and the next targeted therapy - the one an aspirant reading this might need in twenty years - may never get funded at all. The trade-off nobody wants to name plainly This is the real dilemma, not a rhetorical one: upholding a patent protects the innovation pipeline that produces future cures; enforcing that same patent today prices a specific, named person out of a cure that already exists.

Both outcomes are real. Neither side is a strawman. A pharmaceutical executive defending the patent isn't being callous - they're protecting the incentive structure the entire industry depends on. A judge granting compulsory licensing isn't ignoring economics - they're applying a right the Constitution already guarantees. What the Nexavar precedent actually proves India already has the legal tool to resolve this trade-off case by case: compulsory licensing under the Doha Declaration's public-health flexibilities, used exactly once - for Bayer's Nexavar in 2012, cutting its monthly cost from Rs 2.8 lakh to under Rs 9,000.

That single use proves the mechanism works. What it also proves is that India has used it once in twenty years of TRIPS alignment, while facing this exact dilemma repeatedly since. Where the real failure sits The Kerala case reframes the dilemma sharper than the abstract debate does: the 57 adjournments weren't a decision for either side of the trade-off - they were a refusal to decide at all, while a person's remaining time ran out.

If delayed treatment already violates the right to life under Article 21, as the Supreme Court has held, then an unresolved compulsory-licensing petition isn't neutral. It defaults, by delay, to the patent-holder's side - without ever actually weighing the constitutional claim on its merits.

The genuinely hard question isn't "patents or Article 21." It's whether India is willing to let courts and regulators actually decide that trade-off, case by case, on a timeline that respects the fact that for a cancer patient, delay itself is often the final verdict.